Eli Lilly 2011 Annual Report Download - page 100

PROXY STATEMENT
Alfred G. Gilman, M.D., Ph.D. Age 70 Director since 1995
Chief Scientific Officer, Cancer Prevention and Research Institute of Texas
Dr. Gilman is the chief scientific officer of the Cancer Prevention and Research Institute of Texas and regental
professor of pharmacology emeritus at the University of Texas Southwestern Medical Center at Dallas. Dr. Gilman
was on the faculty of the University of Virginia School of Medicine from 1971 to 1981 and was named a professor of
pharmacology there in 1977. He previously served as executive vice president for academic affairs and provost of the
University of Texas Southwestern Medical Center at Dallas, dean of the University of Texas Southwestern Medical
School, and professor of pharmacology at the University of Texas Southwestern Medical Center. He held the
Raymond and Ellen Willie Distinguished Chair of Molecular Neuropharmacology; the Nadine and Tom Craddick
Distinguished Chair in Medical Science; and the Atticus James Gill, M.D., Chair in Medical Science at the university
and was named a regental professor in 1995. He is a director of Regeneron Pharmaceuticals, Inc. Dr. Gilman was a
recipient of the Nobel Prize in Physiology or Medicine in 1994.
Qualifications: Dr. Gilman is a Nobel Prize-winning pharmacologist, researcher, and professor. He has deep
expertise in basic science, including mechanisms of drug action, and experience with pharmaceutical discovery
research. As the former dean of a major medical school, he brings to the board important perspectives of both the
academic and practicing medical communities.
Board committees: public policy and compliance; science and technology (chair)
Karen N. Horn, Ph.D. Age 68 Director since 1987
Retired President, Private Client Services, and Managing Director, Marsh, Inc.
Ms. Horn will serve as the board’s lead director until April 2012. She served as president of private client services
and managing director of Marsh, Inc. from 1999 until her retirement in 2003. Prior to joining Marsh, she was senior
managing director and head of international private banking at Bankers Trust Company; chairman and chief execu-
tive officer of Bank One, Cleveland, N.A.; president of the Federal Reserve Bank of Cleveland; treasurer of Bell Tele-
phone Company of Pennsylvania; and vice president of First National Bank of Boston. Ms. Horn serves as director of
T. Rowe Price Mutual Funds; Simon Property Group, Inc.; and Norfolk Southern Corporation and vice chairman of the
U.S. Russia Foundation. She previously served on the board of Fannie Mae and Georgia-Pacific Corporation.
Ms. Horn has been senior managing director of Brock Capital Group since 2004.
Qualifications: Ms. Horn is a former CEO with extensive experience in various segments of the financial industry,
including banking and financial services. Through her for-profit and her public-private partnership work, she has
significant experience in international economics and finance. Ms. Horn has extensive corporate governance experi-
ence through service on other public company boards in a variety of industries.
Board committees: compensation (chair); directors and corporate governance
John C. Lechleiter, Ph.D. Age 58 Director since 2005
Chairman, President, and Chief Executive Officer
Dr. Lechleiter is chairman, president, and chief executive officer of Eli Lilly and Company. He served as president
and chief operating officer from 2005 to 2008. He joined Lilly in 1979 as a senior organic chemist and has held man-
agement positions in England and the U.S. He was named vice president of pharmaceutical product development in
1993 and vice president of regulatory affairs in 1994. In 1996, he was named vice president for development and
regulatory affairs. Dr. Lechleiter became senior vice president of pharmaceutical products in 1998 and executive vice
president for pharmaceutical products and corporate development in 2001. He was named executive vice president
for pharmaceutical operations in 2004. He is a member of the American Chemical Society and the Business Round-
table. Dr. Lechleiter serves as chairman-elect of Pharmaceutical Research and Manufacturers of America (PhRMA),
and on the boards of United Way Worldwide, Xavier University (Cincinnati, Ohio), Life Sciences Foundation, and the
Central Indiana Corporate Partnership. He also serves on the board of Nike, Inc.
Qualifications: Dr. Lechleiter is our chairman, president, and chief executive officer. Under our corporate gover-
nance guidelines, the CEO is expected to serve on the board of directors. Dr. Lechleiter, a Ph.D. chemist, has over
30 years of experience with the company in a variety of roles of increasing responsibility in research and develop-
ment, sales and marketing, and corporate administration. As a result, he has a deep understanding of pharmaceut-
ical research and development, sales and marketing, strategy, and operations. He also has significant corporate
governance experience through service on other public company boards.
Board committees: none
10